BHC logo

BAUSCH HEALTH COS INC

BHCNYSE
πŸ† #1945 by market capEarnings Oct 29US Equity
$172.85β–Ό $10.04 (βˆ’5.81%)
Simulated price
πŸ””
Track BHC
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 5.8%
7dβ–² 2877.6%
14dβ–² 2948.5%
30dβ–² 2630.6%
ytdβ–² 2390.6%
1yβ–² 2573.6%
🏦Market Cap
$2.13B
Small Cap
πŸ“ˆRevenue Growth (YoY)
+6.7%
Slowing
πŸ“ŠGross Margin
71.8%
High
πŸ’΅FCF Margin
12.8%
Healthy
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
64
Fair

Trading Snapshot

Day Range
$171.24 – $174.15
52-Week Range
$4.33 – $8.00
Volume
$2.80B
Avg Volume
$2.10B
Shares Outstanding
374.0M
Next Earnings
Nov 26, 2026

Fundamentals Snapshot

Annual Revenue
$10.27B
Last Q Revenue
$2.85B
P/E Ratio
-1.9
P/S Ratio
0.2x
EPS (TTM)
$-2.93
Dividend Yield
0.00%
Dilution (1yr)
βˆ’0.4%

Why Investors Own BHC

  • βœ“High-growth profile β€” revenue up +2.4% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 70% gross margin and 17% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BHC logo

BAUSCH HEALTH COS INC

BHC
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$10.3Bβ–² +6.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
70.7%β–Ό βˆ’0.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$2.2Bβ–² +41.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$1.0Bβ–Ό βˆ’20.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
370.5Mβ–Ό βˆ’0.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$19.9Bβ–² +$550M YoY
StockOtter Β· stockotter.space

About BAUSCH HEALTH COS INC

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
64/100

Analyst Price Target

β“˜
Average Target
$217.85
β–² +26.0% Upside
High Target$237.29
Low Target$181.78
Based on 11 analysts

Latest News & Updates